10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Invesco European Growth Fund Comments on MorphoSys

September 05, 2013 | About:
Holly LaFon

Holly LaFon

276 followers
MorphoSys (MOR) is a German biotechnology company with proprietary technology to develop human antibodies for specific diseases. Over the quarter, the company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp., not held by the fund) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.

From Invesco European Fund's second quarter commentary 2013.


Rating: 4.0/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK